Business
TEN-YEAR PIVOTAL DATA REINFORCE THE LONG-TERM DURABILITY OF EDWARDS' RESILIA TISSUE
Edwards Lifesciences, the leading global structural heart innovation company, recently announced 10-year results from the COMMENCE aortic trial, reinforcing the long-term durability and sustained performance of its proprietary RESILIA tissue. The data were presented at the 106th American Association for Thoracic Surgery Annual Meeting.
About this update from Edwards Lifesciences Corporation
[{"type":"text","content":"SINGAPORE, May 4, 2026 /PRNewswire/ -- Edwards Lifesciences, the leading global structural heart innovation company, recently announced 10-year results from the COMMENCE aortic trial, reinforcing the long-term durability and sustained performance of its proprietary RESILIA tissue. The data were presented at the 106th American Association for Thoracic Surgery Annual Meeting.","length":381,"tagName":"p"},{"type":"image","alt":"(PRNewsfoto/Edwards Lifesciences)","displaySize":"","headline":null,"caption":"(PRNewsfoto/Edwards Lifesciences)","className":"","disableSlideshowImg":false,"size":{"original":{"width":305,"height":400,"url":"https://media.zenfs.com/en/prnewswire.com/8c17ccb7150749d20542f52101a0229e"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/YwyjzT2d2ylv9evJU6.lkA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTU1MQ--/https://media.zenfs.com/en/prnewswire.com/8c17ccb7150749d20542f52101a0229e","width":305,"height":400}},"href":"https://mma.prnewswire.com/media/2971491/5950513/EW_BIG_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"Valvular heart disease continues to pose a significant and growing burden on healthcare systems across the Asia‑Pacific region. As clinical evidence increasingly supports earlier intervention in the valve disease pathway, the need for long-term durable valve solutions continues to grow.","length":287,"tagName":"p"},{"type":"text","content":""By extending the evidence base to 10 years, these data further support the long‑term durability and performance of RESILIA tissue," said Vikram Jaisinghani, Senior Director, Medical Affairs, Asia‑Pacific, Edwards Lifesciences. "The COMMENCE trial provides prospective, 10‑year durability data that contribute to the evidence base supporting lifetime management for patients with aortic stenosis."","length":417,"tagName":"p"},{"type":"text","content":"At 10 years, COMMENCE trial data showed that patients treated with Edwards' surgical valves featuring RESILIA tissue experienced:","length":133,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"97.9% freedom from structural valve deterioration (SVD)","length":55,"tagName":"p"}]},{"val":[{"type":"text","content":"97.8% freedom from reoperation due to SVD","length":41,"tagName":"p"}]},{"val":[{"type":"text","content":"98.6% freedom from non-stru...